Research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Read MoreCHÉOS investigators have been successful at effecting widescale change across health systems at all levels, including internationally. Their work has provided vital data to guide policymakers in transforming existing health infrastructure and making evidence-informed decisions.
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Read MoreIn recognition of World Hepatitis Day on July 28, CHÉOS Scientist Dr. Naveed Janjua discusses the BC Hepatitis Testers Cohort
Read MoreCHÉOS researchers address unanswered questions to guide policy and resource allocation for chronic disease management
Read MoreA new CHÉOS-supported study looks to document people’s pregnancy experiences during the pandemic
Read MoreDr. Joseph Puyat leads a team investigating ways to improve and maintain mental wellness in times of mass quarantine and isolation
Read MoreAs we enter into another exciting year of improving health outcomes for BC and beyond, we're reflecting on some of the CHÉOS research from the past year.
Read More